HPHA — Heidelberg Pharma AG Balance Sheet
0.000.00%
- €131.43m
- €123.98m
- €6.85m
Annual balance sheet for Heidelberg Pharma AG, fiscal year end - November 30th, EUR millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.98 | 6.14 | 81.3 | 43.4 | 29.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.51 | 1.45 | 1.45 | 2.32 | 5.95 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.52 | 9.01 | 87.9 | 56.6 | 47.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.11 | 3.67 | 3.72 | 3.85 | 3.49 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 19.6 | 21.7 | 101 | 70.4 | 60.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.63 | 14.9 | 27.9 | 19.8 | 8 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.73 | 15 | 33.9 | 21 | 29.9 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 12.9 | 6.7 | 66.6 | 49.3 | 30.9 |
Total Liabilities & Shareholders' Equity | 19.6 | 21.7 | 101 | 70.4 | 60.7 |
Total Common Shares Outstanding |